Description
Defactinib inhibits FAK and displays anticancer activity. In ovarian cancer models, this compound decreases cell proliferation, induces apoptosis, and decreases tumor weight.
Defactinib
Product ID D1722
Cas No. 1073154-85-4
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 1073154-85-4 |
|---|---|
| Purity | ≥98% |
| Formula | C20H21F3N8O3S |
| Formula Wt. | 510.49 |
| IUPAC Name | N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide |
| Synonym | VS-6063, PF-04554878 |
| Solubility | DMSO 5 mg/mL warmed (9.79 mM) Water Insoluble Ethanol Insoluble |
| Appearance | White to off white powder |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet |
References
Lee BY, Timpson P, Horvath LG, et al. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015 Feb;146C:132-149. PMID: 25316657.
Kang Y, Hu W, Ivan C, et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95. PMID: 24062525.